Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The aim of this study was to evaluate the profile of patients on antiresorptive therapies for cancer treatment and assess presence of oral lesions, oral hygiene status, and knowledge regarding medication-related osteonecrosis of the jaw (MRONJ). Materials and Methods: This was an observational cross-sectional study that evaluated patients treated with antiresorptive medication at a single cancer hospital. Clinical data were collected and oral examination was performed to assess patient oral health. Results: From July 2017 to December 2018, 90 patients were assessed; 64 were female and 26 were male, and the mean age was 61 years. The most common drug was an intravenous bisphosphonate, zoledronic acid. Among the 90 patients, 47 presented with some type of oral disease, isolated or associated. Among these 47 patients, 9 patients (10%) developed osteonecrosis. Oral hygiene was evaluated, and most patients, with or without MRONJ, presented with regular to poor condition. Regarding patient knowledge of the risks of MRONJ and the risks associated with dental surgery, 60% stated that they were not aware of the risks. Conclusion: Identifying the profile of patients and their needs facilitates not only the preventive process, but also the emergence of new therapeutic options. Our study shows that most patients are weakened both by metastatic disease and antineoplastic treatment as well as by issues associated with aging because most were over 60 years of age. Collectively, this information should be considered for management of preventive and therapeutic measures.
Abstract
Objectives: The aim of this study was to evaluate the profile of patients on antiresorptive therapies for cancer treatment and assess presence of oral lesions, oral hygiene status, and knowledge regarding medication-related osteonecrosis of the jaw (MRONJ). Materials and Methods: This was an observational cross-sectional study that evaluated patients treated with antiresorptive medication at a single cancer hospital. Clinical data were collected and oral examination was performed to assess patient oral health. Results: From July 2017 to December 2018, 90 patients were assessed; 64 were female and 26 were male, and the mean age was 61 years. The most common drug was an intravenous bisphosphonate, zoledronic acid. Among the 90 patients, 47 presented with some type of oral disease, isolated or associated. Among these 47 patients, 9 patients (10%) developed osteonecrosis. Oral hygiene was evaluated, and most patients, with or without MRONJ, presented with regular to poor condition. Regarding patient knowledge of the risks of MRONJ and the risks associated with dental surgery, 60% stated that they were not aware of the risks. Conclusion: Identifying the profile of patients and their needs facilitates not only the preventive process, but also the emergence of new therapeutic options. Our study shows that most patients are weakened both by metastatic disease and antineoplastic treatment as well as by issues associated with aging because most were over 60 years of age. Collectively, this information should be considered for management of preventive and therapeutic measures.
참고문헌 (18)
- Ourania Nicolatou-Galitis, "Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 127(2), pp.117~135 (2019), Elsevier BV[DOI]
- Coleman RE., "Skeletal complications of malignancy", Cancer, 80(8 Suppl), pp.1588~1594 (1997)[DOI]
- Onur Şahin, "Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation", 대한구강악안면외과학회지, 45(2), pp.108~115 (2019), 대한구강악안면외과학회[DOI]
- Salvatore L. Ruggiero, "American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update", Journal of Oral and Maxillofacial Surgery, 72(10), pp.1938~1956 (2014), Elsevier BV[DOI]
- Antonio Fabrizio Nifosì, "Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology", 대한구강악안면외과학회지, 45(1), pp.3~8 (2019), 대한구강악안면외과학회[DOI]
- Abdulrhman Al Abdullateef, "Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) – A primary prevention strategy", Saudi Pharmaceutical Journal, 28(6), pp.771~778 (2020), Elsevier BV[DOI]
- Andrew Sturrock, "Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England", BMJ Open, 9(3), pp.e024376~ (2019), BMJ[DOI]
- John G. Greene, "The Simplified Oral Hygiene Index", The Journal of the American Dental Association, 68(1), pp.7~13 (1964), Elsevier BV[DOI]
- V. Patel, "New cancer therapies and jaw necrosis", British Dental Journal, 219(5), pp.203~207 (2015), Springer Science and Business Media LLC[DOI]
- Marcus J. Heufelder, "Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 117(6), pp.e429~e435 (2014), Elsevier BV[DOI]
- Claudine Tsao, "Oral Health Risk Factors for Bisphosphonate-Associated Jaw Osteonecrosis", Journal of Oral and Maxillofacial Surgery, 71(8), pp.1360~1366 (2013), Elsevier BV[DOI]
- Shaiba Sandhu, "Osteonecrosis of the jaw and dental extractions: A single-center experience", Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 130(5), pp.515~521 (2020), Elsevier BV[DOI]
- Victor Lousan do Nascimento Poubel, "The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review", Journal of Cranio-Maxillofacial Surgery, 46(2), pp.245~256 (2018), Elsevier BV[DOI]
- Regina Landesberg, "Potential pathophysiological mechanisms in osteonecrosis of the jaw", Annals of the New York Academy of Sciences, 1218(1), pp.62~79 (2011), Wiley[DOI]
- Elise Gaudin, "Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis", Journal of Clinical Periodontology, 42(10), pp.922~932 (2015), Wiley[DOI]
- H. Tsurushima, "Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats", International Journal of Oral and Maxillofacial Surgery, 42(11), pp.1481~1487 (2013), Elsevier BV[DOI]
- Dimopoulos MA, "Reduction of osteonecrosis of the jaw(ONJ)after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid", Ann Oncol, 20, pp.117~120 (2009)[DOI]
- Annalisa Bramati, "Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases", Journal of Bone and Mineral Metabolism, 33(1), pp.119~124 (2015), Springer Science and Business Media LLC[DOI]